Payment overview · 2025
General Payments
$709.85
40 reported records · 15 companies
Healthcare provider profile · identity verified
Harold Edward Ayers, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PT PLEASANT, WV · NPI 1780783670
Verified facts
What the public records show
CMS Open Payments records show Harold Edward Ayers, MD received $709.85 in general payments during 2025 across 40 reported records.
ABBVIE INC. accounted for 48.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $343.42 | 48.4% | 19 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $37.17 | 5.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.79 | 4.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.39 | 4.8% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $34.33 | 4.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.97 | 4.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.36 | 4.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.65 | 4.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.15 | 3.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.57 | 3.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.76 | 2.6% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $18.33 | 2.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.28 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.27 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.41 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $709.85 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $264.18 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $237.82 | 13 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $76.60 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $62.33 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $34.33 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.97 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 77 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 99 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 111 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
99 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
111 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
267 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 733 | 167 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 682 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 591 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 587 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 562 | 130 |
| Metoprolol Succinate | Metoprolol Succinate | 525 | 116 |
| Losartan Potassium | Losartan Potassium | 481 | 108 |
| Gabapentin | Gabapentin | 442 | 70 |
| Metformin Hcl | Metformin Hcl | 428 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 407 | 103 |
| Lisinopril | Lisinopril | 373 | 81 |
| Furosemide | Furosemide | 332 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 323 | 68 |
| Potassium Chloride | Potassium Chloride | 314 | 75 |
| Alprazolam | Alprazolam | 299 | 47 |
| Eliquis | Apixaban | 267 | 50 |
| Sertraline Hcl | Sertraline Hcl | 259 | 47 |
| Ozempic | Semaglutide | 232 | 41 |
| Ezetimibe | Ezetimibe | 229 | 52 |
| Omeprazole | Omeprazole | 221 | 50 |
| Mounjaro | Tirzepatide | 210 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 43 |
| Carvedilol | Carvedilol | 156 | 37 |
| Januvia | Sitagliptin Phosphate | 148 | 16 |
| Cefuroxime | Cefuroxime Axetil | 146 | 94 |
| Bupropion Xl | Bupropion Hcl | 134 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 124 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 32 |
| Donepezil Hcl | Donepezil Hcl | 122 | suppressed |
| Prednisone | Prednisone | 122 | 56 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 117 | 37 |
| Montelukast Sodium | Montelukast Sodium | 116 | 27 |
| Meloxicam | Meloxicam | 114 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 111 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 111 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 110 | 16 |
| Torsemide | Torsemide | 106 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 19 |
| Linzess | Linaclotide | 99 | 22 |
| Solifenacin Succinate | Solifenacin Succinate | 99 | 25 |
| Simvastatin | Simvastatin | 94 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 93 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 27 |
| Trulicity | Dulaglutide | 93 | 18 |
| Primidone | Primidone | 92 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 18 |
| Clonazepam | Clonazepam | 80 | 13 |
| Jardiance | Empagliflozin | 77 | 18 |
| Trazodone Hcl | Trazodone Hcl | 73 | 13 |
| Allopurinol | Allopurinol | 71 | 17 |
| Mirtazapine | Mirtazapine | 65 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 65 | 13 |
| Cephalexin | Cephalexin | 63 | 35 |
| Buspirone Hcl | Buspirone Hcl | 59 | 12 |
| Aripiprazole | Aripiprazole | 58 | suppressed |
| Atenolol | Atenolol | 57 | 16 |
| Indapamide | Indapamide | 55 | 13 |
| Lorazepam | Lorazepam | 55 | 12 |
| Glipizide | Glipizide | 54 | 15 |
| Lamotrigine | Lamotrigine | 54 | suppressed |
| Nifedipine Er | Nifedipine | 53 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 31 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Spironolactone | Spironolactone | 52 | 15 |
| Cefdinir | Cefdinir | 51 | 41 |
| Irbesartan | Irbesartan | 51 | 12 |
| Synthroid | Levothyroxine Sodium | 51 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Mupirocin | Mupirocin | 46 | 38 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 16 |
| Nitroglycerin | Nitroglycerin | 45 | 34 |
| Baclofen | Baclofen | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 15 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | 19 |
| Movantik | Naloxegol Oxalate | 42 | suppressed |
| Repatha Sureclick | Evolocumab | 42 | 11 |
| Sucralfate | Sucralfate | 42 | 11 |
| Ketoconazole | Ketoconazole | 41 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | 12 |
| Finasteride | Finasteride | 40 | 11 |
| Glimepiride | Glimepiride | 40 | 12 |
| Ibuprofen | Ibuprofen | 40 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Ursodiol | Ursodiol | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 26 |
| Sotalol | Sotalol Hcl | 37 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 36 | 12 |
| Famotidine | Famotidine | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 16 |
| Diazepam | Diazepam | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 12 |
| Temazepam | Temazepam | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 11 |
| Fluconazole | Fluconazole | 28 | 14 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 22 | suppressed |
| Ertapenem | Ertapenem Sodium | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Ofloxacin | Ofloxacin | 17 | 14 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 13 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 11 |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $709.85 · 40 records | ABBVIE INC. | CAPVAXIVE, CREON, Dexcom G6 Transmitter, GARDASIL 9, JARDIANCE, Kerendia, Korlym, LINZESS, M-M-R II, OTEZLA, Ohtuvayre, QULIPTA, REPATHA, REXULTI, TEZSPIRE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, WAKIX, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error